Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Ipsen
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Amgen
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stanford University
Nordic Nanovector
University of Pennsylvania
Brown University
ADC Therapeutics S.A.
Merck Sharp & Dohme LLC
ADC Therapeutics S.A.
Fred Hutchinson Cancer Center
Gilead Sciences
University of Washington
Pfizer
Merck Sharp & Dohme LLC
Boehringer Ingelheim
Dartmouth-Hitchcock Medical Center
GlaxoSmithKline
Aptevo Therapeutics
Massachusetts General Hospital
Hoffmann-La Roche
Novartis
Ohio State University Comprehensive Cancer Center